Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.

Dent J (Basel) · 2016 · PMC5806937 · PMID 29563470

Europe PMC DOI

hedged sentence

0.0910

closest p · 1.8× alpha

0.0910

boldest claim

The sentences

a strong trendp = 0.091so close (0.05 < p ≤ 0.1)

Interestingly, there was a strong trend towards prolonged survival in patients receiving zoledronic acid compared to placebo (546 days vs. 464 days; p = 0.091).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.